These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 15826896)

  • 1. Polio immunization policy in Mexico: economic assessment of current practice and future alternatives.
    Mascareñas A; Salinas J; Tasset-Tisseau A; Mascareñas C; Khan MM
    Public Health; 2005 Jun; 119(6):542-9. PubMed ID: 15826896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM
    Vaccine; 2008 Apr; 26(16):2034-40. PubMed ID: 18339460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The costs of future polio risk management policies.
    Tebbens RJ; Sangrujee N; Thompson KM
    Risk Anal; 2006 Dec; 26(6):1507-31. PubMed ID: 17184394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM; Sharma S; Tripathi B; Alvarez FP
    Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of routine polio immunization in the post-certification era.
    Sutter RW; Cáceres VM; Mas Lago P
    Bull World Health Organ; 2004 Jan; 82(1):31-9. PubMed ID: 15106298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ
    Bull World Health Organ; 2004 Jan; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of house-to-house versus fixed-site oral poliovirus vaccine delivery strategies in a mass immunization campaign in Egypt.
    Linkins RW; Mansour E; Wassif O; Hassan MH; Patriarca PA
    Bull World Health Organ; 1995; 73(5):589-95. PubMed ID: 8846484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
    Miller MA; Sutter RW; Strebel PM; Hadler SC
    JAMA; 1996 Sep; 276(12):967-71. PubMed ID: 8805731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction of inactivated polio vaccine (IPV) into the routine immunization schedule of South Africa.
    Schoub BD
    Vaccine; 2012 Sep; 30 Suppl 3():C35-7. PubMed ID: 22939019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The perspective of global eradication of poliomyelitis].
    Knolle H; Egli A; Candrian U
    Gesundheitswesen; 2004 Jan; 66(1):1-6. PubMed ID: 14767784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia.
    Tucker AW; Isaacs D; Burgess M
    Aust N Z J Public Health; 2001 Oct; 25(5):411-6. PubMed ID: 11688618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health and Economic Outcomes Associated with Polio Vaccine Policy Options: 2019-2029.
    Kalkowska DA; Thompson KM
    Risk Anal; 2021 Feb; 41(2):364-375. PubMed ID: 33590519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Economic impact of introducing the injectable inactivated polio vaccine in Colombia].
    Alvis N; De la Hoz F; Narváez J
    Rev Panam Salud Publica; 2010 May; 27(5):352-9. PubMed ID: 20602069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polio inactivated vaccine costs into routine childhood immunization in Brazil.
    Sartori AM; Vicentine MP; Gryninger LC; Soárez PC; Novaes HM
    Rev Saude Publica; 2015; 49():8. PubMed ID: 25741645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau.
    Aaby P; Hedegaard K; Sodemann M; Nhante E; Veirum JE; Jakobsen M; Lisse I; Jensen H; Sandström A
    Vaccine; 2005 Feb; 23(14):1746-51. PubMed ID: 15705481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.